Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Colorcon
AstraZeneca
Baxter
Moodys

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,368,469

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,368,469 protect, and when does it expire?

Patent 7,368,469 protects ALTACE and is included in two NDAs.

This patent has forty-seven patent family members in thirty-two countries.

Summary for Patent: 7,368,469
Title:Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
Abstract:Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.
Inventor(s): Scholkens; Bernward (Kelkheim, DE), Bender; Norbert (Hofheim, DE), Rangoonwala; Badrudin (Hofheim, DE), Dagenais; Gilles (St.-Nicholas, CA), Gerstein; Hertzel (Hamilton, CA), Yusuf; Salim (Carlisle, CA)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt, DE)
Application Number:11/490,061
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,368,469

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 AB RX Yes No   Start Trial   Start Trial METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH   Start Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 AB RX Yes No   Start Trial   Start Trial METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH   Start Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-003 Jan 28, 1991 AB RX Yes No   Start Trial   Start Trial METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH   Start Trial
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 AB RX Yes Yes   Start Trial   Start Trial METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Mallinckrodt
Baxter
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.